Maternal Subclinical Hypothyroidism in the first trimester is not Associated with Gestational Diabetes Mellitus

CURRENT STATUS: POSTED

Ping Li
Third Affiliated Hospital of Sun Yat-Sen University
ORCiD: https://orcid.org/0000-0003-2297-7739

Xinjuan Chen
third affiliated hospital of Sun Yat-sen University

Jinhui Cui
third affiliated hospital of Sun Yat-sen University

Zhaoran Meng
Third Affiliated Hospital of Sun Yat-Sen University

Jianhui Fan
third affiliated hospital of Sun Yat-sen University

Shuo Lin
gzlinshuo@hotmail.com Corresponding Author

DOI: 10.21203/rs.2.17829/v1

SUBJECT AREAS
Endocrinology & Metabolism

KEYWORDS
Thyroid stimulating hormone, First trimester, Gestational diabetes mellitus
Abstract

Background: To explore the association between subclinical hypothyroidism (SCH) during the first trimester and gestational diabetes mellitus (GDM) that was happened later on in our cohort.

Methods: A total of 6530 pregnant women who first visited before 13 + 6 gestational weeks and accepted routinely prenatal services in the third affiliated hospital of Sun Yat-Sen University from January 2015 to September 2018 were finally met the inclusion criteria and recruited. Thyroid functions (TSH, free T4 (FT4) and TPOAb) were performed at the first visit and a 2h 75-g oral glucose tolerance test was performed between 24-28 weeks. Chi-square test and multivariate logistic regression were used to evaluate the association between SCH and GDM.

Results: Though SCH group was divided into subgroups according TPOAb status and TSH levels, the incidence of GDM was no change when compared with the normal group (all P > 0.05). No matter adjusting or not for maternal age, maternal pregestational body max index, parity and educational level, the results showed elevated TSH was not associated GDM (all P > 0.05). TPOAb status also had no effect on the incidence of GDM either before or after adjustment (P > 0.05).

Conclusion: Maternal SCH in the first trimester was not associated with GDM, regardless of the TPOAb status or the TSH levels.

Background

Thyroid disease is the second most frequent endocrine disorder among reproductive-aged women\(^1\). As the increased serum human chorionic gonadotropin (HCG) concentration and synthesis of thyroxine-binding globulin (TBG), serum thyroid stimulating hormone (TSH) concentrations during pregnancy are not the same as those observed in nonpregnant women\(^2\), and at the same time makes the thyroid disorder being more likely to occur during pregnancy\(^3\). Subclinical hypothyroidism (SCH) is one of the common thyroid disorder during pregnancy and is characterized by an elevated TSH level and a normal free thyroxine (fT4) level\(^4\). According the American Thyroid Association (ATA) guideline (2011), SCH is estimated to affect up to 15% of pregnant women in the United States and 28% of pregnant women in China\(^5, 6\). As the high incidence, increasing studies began to reassessed whether SCH, the less severe form of thyroid disease, was linked to adverse pregnancy...
outcomes. However, results were still conflicting\textsuperscript{7-10}.

Thyroid disease and diabetes mellitus are two closely associated disorders in non-pregnant populations\textsuperscript{11}. Lack of thyroid hormone is associated with insulin resistance and glucose intolerance\textsuperscript{12}. Gestational diabetes mellitus (GDM) which is defined as “any degree of glucose intolerance with the onset or first recognition during pregnancy” is another common endocrine disorder during pregnancy\textsuperscript{13}. GDM is usually the result of β-cell dysfunction on a background of chronic insulin resistance during pregnancy and thus both β-cell impairment and tissue insulin resistance represent critical components of the pathophysiology of GDM\textsuperscript{14}. Whether SCH during pregnancy has the effect on insulin resistance and glucose intolerance and then leads to GDM, several studies have evaluated the relationship, but the result remains controversial. Because of this, we designed to evaluate the association between SCH during the first trimester and GDM that was happened later on in our cohort.

Materials And Methods

Subjects

The study was conducted in the third affiliated hospital of Sun Yat-Sen University from January 2015 to September 2018 and approved by the Human Research Ethics Committee of the hospital. The characteristics of the study population were shown in Figure 1. A total of 8872 pregnant women who first visited before 13\textsuperscript{+6} gestational weeks and accepted routinely prenatal services were collected. The following pregnant women were excluded: 124 women with personal or family history of thyroid diseases, 68 cases of multiple pregnancy, 46 women with pregestational diabetes mellitus, 74 women using drugs that may influence thyroid function and 230 women lack of the oral glucose tolerance test (OGTT) results.

Methods

Thyroid function was performed at the first visit during the first trimester. Serum samples were obtained in the morning after at least 8-hour fasting for all study participants. Serum TSH, free thyroxine (FT4) and thyroid peroxidase antibody (TPOAb) were measured at the clinical analysis
laboratory by an automated two step chemiluminescent immunoassay on an ARCHITECT analyzer (Abbott Diagnostics). The normal range of TSH in the first trimester was adopted from the 2011 ATA guidelines (0.1- 2.5 mIU/L)[15]. The reference ranges for TPOAb (<5.61 IU/mL) and FT4 (9.01 – 19.05 pmol/L) were provided by the manufacturer. Based on the TSH and TPOAb level, the following pregnant women were excluded: TSH < 0.1 mIU/L (n=681), TSH > 10 mIU/L (n=7), or TSH normal but TPOAb positive (n=1114). Ultimately, we divided the pregnant women into two groups: the normal group (TSH normal and TPOAb negative) (n=5957) and the SCH group (TSH > 2.5 mIU/L) (n=573).

A 2h 75-g OGTT was performed between 24-28 weeks in the morning after at least 8-hour fasting.

Blood glucose level was measured using the glucose oxidase method (Roche Diagnostics). The diagnosis criteria for GDM was based on the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (i.e., one or more plasma venous glucose values ≥ 0 h, 5.1 mmol/L; 1 h, 10.0 mmol/L; or 2 h, 8.5 mmol/L)[16].

Patients’ baseline characteristics were recorded at the first visit, including age, pregestational body mass index (BMI, BMI=weight (kg) / height (m²)), parity, family or personal history diseases (thyroid disease, hypertension, pregestational diabetes mellitus and systemic lupus erythematosus) and education level.

Statistical analysis

Data were presented as median (interquartile range) for non-normally distributed data and frequency (percentage) for categorical variables. Chi-square test was used to test for differences in variables between groups. Multivariate logistic regression was used to evaluate the association between SCH and GDM. The results are represented as odds ratios (ORs) and 95% confidence intervals (95% CIs). P < 0.05 was considered statistically significant. SPSS19.0 software (SPSS, Inc., Chicago, IL) was used for analysis.

Results
In this study, 573 pregnant women were diagnosed as SCH and the incidence of SCH was 6.69% (573/8562). A total of 6530 pregnant women were ultimately met the inclusion criteria, including 573 SCH women and 5957 normal women (TSH normal and TPOAb negative). The characteristics of participants were shown in Table 1. The average level of TSH in SCH group and normal group was 3.02 (2.70–3.64) mIU/L and 0.94 (0.56–1.40) mIU/L respectively. The three times of blood glucose on 75 g-OGTT were not significantly different between SCH group and normal group [0 hour: 4.17 mmol/L (3.99–4.38) vs 4.16 mmol/L (3.97–4.39), P = 0.730; 1 hour: 7.61 mmol/L (6.64–8.66) vs 7.68 mmol/L (6.64 – 8.75), P = 0.449; 2 hour: 6.66 mmol/L (5.85–7.68) vs 6.75 mmol/L (5.93–7.74), P = 0.142]. The age, preBMI and education levels were also not significantly different between the two groups (all P > 0.05). However, there was more nullipara in SCH group than in normal group (58.30% vs 50.70%, P = 0.000).

Table 1
Basic characteristics between subclinical hypothyroidism and normal pregnant women divided by the first-trimester TSH concentrations *

| Characteristics                              | Total (n = 6530) | Normal (n = 5957) | SCH (n = 573) | P     |
|----------------------------------------------|------------------|-------------------|--------------|-------|
| Maternal age (years)                         | 29(27–32)        | 29(27–32)         | 29(27–32)    | 0.695 |
| Pregestational BMI (kg/m²)                   | 20.31(18.82–22.21) | 20.31(18.82–22.21) | 20.31(18.67–22.06) | 0.393 |
| Parity                                       |                  |                   |              |       |
| Nullipara (%)                                | 3352(51.33)      | 3018(50.70)       | 334(58.30)   | 0.000 |
| Multipara (%)                                | 3178(48.67)      | 2939(49.30)       | 239(41.70)   |       |
| Education level                              |                  |                   |              |       |
| High school or lower Bachelor or higher      | 3515(53.83)      | 3199(53.70)       | 316(55.10)   | 0.507 |
| Thyroid function at early pregnancy         |                  |                   |              |       |
| TPOAb (IU/mL)                                | 0.22(0.01–0.51)  | 0.20(0.01–0.46)   | 0.50(0.10–35.75) | 0.000 |
| FT4 (pmol/L)                                 | 1.02(0.60–1.58)  | 1.37(12.26–14.35) | 12.51(11.50–13.47) | 0.000 |
| TSH (uiU/mL)                                 | 4.17(3.97–4.39)  | 4.16(3.97–4.39)   | 4.17(3.99–4.38) | 0.730 |
| Blood glucose on 75-g OGTT                   |                  |                   |              |       |
| 0 hour (mmol/L)                              | 7.68(6.64–8.74)  | 7.68(6.64–8.75)   | 7.61(6.64–8.66) | 0.449 |
| 1 hour (mmol/L)                              | 6.74(5.92–7.73)  | 6.75(5.93–7.74)   | 6.66(5.85–7.68) | 0.142 |
| 2 hour (mmol/L)                              |                  |                   |              |       |

* Medians (interquartile ranges)

TSH, thyroid stimulating hormone; BMI, body mass index; TPOAb: thyroid peroxidase antibody; fT4, free thyroxine 4; OGTT, oral glucose tolerance test
Table 2
Comparison the incidence of gestational diabetes mellitus between subclinical hypothyroidism and normal pregnant women divided by TSH levels and TPOAb status in early pregnancy.

|                      | GDM (%)     | χ²       | P       |
|----------------------|-------------|----------|---------|
| Normal               | 16.3 (971/5957) | Reference | Reference |
| Subclinical hypothyroidism |            |          |         |
| TSH(H) TPOAb(-/+ )  | 14.1(81/573) | 1.811    | 0.178   |
| TSH(H) TPOAb(-)     | 13.8(53/384) | 1.662    | 0.197   |
| TSH(H) TPOAb(-)     | 13.5(46/340) | 1.823    | 0.177   |
| TSH(H) TPOAb(-)     | 15.9(7/44)   | 0.005    | 0.944   |
| TSH(H) TPOAb(+)     | 14.8(28/189) | 0.297    | 0.586   |
| TSH(H) TPOAb(+)     | 12.9(18/140) | 1.193    | 0.275   |
| TSH(H) TPOAb(+)     | 20.4(10/49)  | 0.600    | 0.439   |

GDM, gestational diabetes mellitus; TSH, thyroid stimulating hormone; TPOAb: thyroid peroxidase antibody
*TSH(H₁): > 2.5 uIU/mL, < 4.0 uIU/mL; †TSH(H₂): ≥ 4.0 uIU/mL.

As shown in Fig. 2, the incidence of GDM was compared between the SCH and normal pregnant women. SCH group was further divided into subgroups according TSH levels and TPOAb status in the first trimester. There were 384 TPOAb negative women and 189 TPOAb positive women in SCH groups. More than 80 percent SCH women (83.77%, 480/573) had the TSH slightly elevated (between 2.5 mIU/L to 4.0 mIU/L) and just 16.23% (93/573) women had the TSH level ≥ 4.0 mIU/L. Though SCH group was divided into TPOAb negative and TPOAb positive subgroups, the incidence of GDM was not different when compared with the normal group (TPOAb negative vs normal: 13.8% vs 16.3%, χ² = 1.662, P = 0.197; TPOAb positive vs normal: 14.8% vs 16.3%, χ² = 0.297, P = 0.586). Then we further subdivided the SCH group women according to the different elevated TSH levels (TSH (H₁): > 2.5 uIU/mL, < 4.0 uIU/mL) and high level (TSH(H₂): ≥ 4.0 uIU/mL), and then compared the incidence of GDM with the normal group. In TSH (H₁) group, we observed no difference in the incidence of GDM (TPOAb(-): 13.5% vs 16.3%, χ² = 1.823, P = 0.177; TPOAb(+) : 12.9% vs 16.3%, χ² = 1.193, P = 0.275). In TSH (H₂) group, we got the same conclusion (TPOAb(-): 15.9% vs 16.3%, χ² = 0.005, P = 0.944; TPOAb(+) : 20.4% vs 16.3%, χ² = 0.600, P = 0.439).

We used a multivariate logistic regression analysis to investigate whether SCH in the first trimester associated with GDM, as shown in Table 3. The results showed that no matter adjusting or not for age, pregestational body mass index (preBMI), parity and educational level, elevated TSH was not associated GDM that was happen later on (all P > 0.05). TPOAb status also had no effect on the
incidence of GDM either before or after adjustment (P > 0.05).

### Table 3
Multivariate logistic regression analysis for the association of SCH in the first trimester and GDM

| SCH | Unadjusted model OR (95% CI) | P | Adjusted model1 OR (95% CI) | P | Adjusted model2 OR (95% CI) | P |
|-----|-------------------------------|---|-----------------------------|---|-----------------------------|---|
| TSH(N) | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) |
| TPOAb(-) | 0.772(0.587–1.014) | 0.063 | 0.787(0.595–1.041) | 0.093 | 0.798(0.581–1.096) | 0.164 |
| TSH(H1) | 1.215(0.724–2.041) | 0.461 | 1.175(0.688–2.007) | 0.555 | 1.208(0.657–2.220) | 0.543 |

* TSH(H1): > 2.5 uIU/mL; < 4.0 uIU/mL; †TSH(H2): ≥ 4.0 uIU/mL.

### Discussion
The purpose of the present study was to evaluate the association between SCH during the first trimester and the risk of GDM in our cohort and we also took TPOAb status and TSH level into consideration. The glucose levels of OGTT were shown no differences between SCH women and euthyroid women. The incidence of GDM was no change as the TSH level increased in either TPOAb negative or TPOAb positive SCH women. We also used the multivariate logistic regression analysis to adjust the confounders and the result did no change after adjusted for maternal age, educational levels and preBMI. Thus, our study demonstrated that maternal SCH in the first trimester was not associated with GDM that was happened later on. Presently, the association between SCH and GDM is still conflicting. Different cutoffs that are adopted for the diagnosis of SCH, highly varied gestational ages in which thyroid functions are tested, as well as TPOAb status are the main reasons for different results. In our study, thyroid function was performed before 13+6 gestational weeks. We adopted the 2011 ATA guideline for the diagnostic cutoff and the reference intervals for TSH is 0.1–2.5 mIU/L in the first trimester. TPOAb status was also taken into account. In Ying et al.'s study, they used 0.06–3.83 mIU/L as the reference intervals for TSH in the first trimester that was established at their institution. They showed that elevated TSH combined with positive TPOAb was associated with a 3-fold increased risk for GDM compared to euthyroid women in the first trimester (RR: 3.26, 95% CI: 1.55 to 6.84) [17]. However, in elevated TSH but TPOAb negative women, no relationship was found between SCH and GDM (RR: 0.55, 95% CI: 0.12 to 2.51). Karakosta's study showed that there was no obviously increased risk of GDM in SCH women with TPOAb negative in early pregnancy (RR: 1.4, 95% CI: 0.5 to 3.8), whereas those with an elevated TSH and autoantibodies were at a four-fold increased risk for GDM (RR: 4.3, 95% CI: 2.1 to 8.9) [18]. Different from us, they tested the thyroid functions before 15 gestational weeks and the reference intervals of TSH were 0.05–2.53 mIU/L. Our finding was agreed with several other investigations. In Arbib et al.'s study, they used the same reference range of TSH as us and showed that SCH in the first trimester was not associated with an increased risk for GDM either in TSH 2.5–4.0 mIU/L group or in TSH ≥ 4.0 mIU/L group [17]. In Chen et al.'s study, no significant difference in the incidence of GDM was observed between euthyroid women and SCH women (3.74% vs 22.16%, P = 0.112). In their study, subjects were recruited from all trimesters and no stratification was performed based on gestational age. The reference ranges for TSH was based on the local trimester-specific reference values (first trimester, TSH 0.09–3.47 mIU/L) [18]. Unlike our study, the limitations of the above two studies were that they did not analyze the effect of TPOAb status on the association and did not adjust for confounders. Different diagnosis criteria of GDM have been used in different studies examining the relationship between SCH and GDM, and this may also lead to the inconsistent results. Currently, there is lack of unified diagnostic criteria for GDM and separate studies adopted the test methods and the cut-offs according their own national guidelines [17–20]. In our study, we used the IADPSG diagnosis criteria that is accepted by many countries [17, 21, 22]. Furthermore, most studies investigating SCH and adverse obstetrical outcomes suggest that degrees of TSH elevation are associated with increased risks to the pregnancy [23, 24]. In Tudela’s study, the predicted percent of gestational diabetes increased from 1.9–4.9% as thyrotropin increased from 0.001 to 10 milliunits/L (P = 0.001) [20]. In our study, the average level of TSH in SCH group was 3.02(2.70–3.64) mIU/L. More than 80 percent SCH women (83.77%) had the TSH slightly elevated (between 2.5 mIU/L to 4.0 mIU/L) and only 16.23% women had the TSH level ≥ 4.0 mIU/L. This might be one reason why our study did not show that TSH elevation increased the risk of GDM.

There are some limitations in our research. Firstly, we conducted a single-center study and this might limit the widespread application. Secondly, we did not establish the trimester-specific reference values for thyroid function in our center. As substantial variation exists between populations, elevations in serum TSH concentrations during pregnancy should ideally be defined using pregnancy- and population-specific reference ranges. Finally, the number of women with obviously elevated TSH was lower which restricted the further stratified analysis of the
relationship between SCH and GDM. Thus, further study needs to be conducted to confirm our findings. In summary, SCH is variably associated with an increased risk of GDM in separate studies. This is due to many factors. In our study, we demonstrated that maternal SCH in the first trimester was not associated with GDM in our cohort, regardless of the TPOAb status or the TSH levels.

Declarations

Competing interests
We declare that we have no conflict of interest.

Funding
This study was supported by the research grant from the Science and Technology Planning Project of Guangdong province (2017A020215026). The funder had no role in the design of study, data collection and analysis, or presentation of the results.

Authors’ contributions
PL conceived the idea for the research, wrote the framework, and drafted the manuscript as the principal author. XJC made substantial contributions to the study conception and framework and design. JHC made substantial contributions to the study conception and framework. ZRM made substantial contributions to the study conception and framework. JHF was responsible for the revision of the paper. HYH was responsible for the revision of the paper. SL participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.

Acknowledgments
We gratefully acknowledge all the participants in our study. We are also grateful to the Third Affiliated Hospital of Sun Yat-Sen University.

References

1. Rashid M, Rashid MH. Obstetric management of thyroid disease. Obstet Gynecol Surv. 2007;62(10):680–8; quiz 691.
2. CROOKS J, ABOUL-KHAIR SA, TURNBULL AC, HYTTEN FE. THE INCIDENCE OF GOITRE DURING PREGNANCY. Lancet. 1964;2(7355):334–6.
3. Feldt-Rasmussen U, Mathiesen ER. Endocrine disorders in pregnancy: physiological and hormonal aspects of pregnancy. Best Pract Res Clin Endocrinol Metab. 2011;25(6):875–84.
4. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142–54.
5. Blatt AJ, Nakamoto JM, Kaufman HW. National status of testing for hypothyroidism during pregnancy and postpartum. J Clin Endocrinol Metab. 2012;97(3):777–84.
6. Li C, Shan Z, Mao J, et al. Assessment of thyroid function during first-trimester pregnancy: what is the rational upper limit of serum TSH during the first trimester in Chinese pregnant women. J Clin Endocrinol Metab. 2014;99(1):73–9.
7. Arbib N, Hadar E, Sneh-Arrib O, Chen R, Wiznitzer A, Gabbay-Benziv R. First trimester thyroid stimulating hormone as an independent risk factor for adverse pregnancy outcome. J Matern Fetal Neonatal Med. 2017;30(18):2174–8.
8. Chen LM, Du WJ, Dai J, et al. Effects of subclinical hypothyroidism on maternal and perinatal outcomes during pregnancy: a single-center cohort study of a Chinese population. PLoS One. 2014;9(10):e109364.
9. Ong GS, Hadlow NC, Brown SJ, Lim EM, Walsh JP. Does the thyroid-stimulating hormone measured concurrently with first trimester biochemical screening tests predict adverse pregnancy outcomes occurring after 20 weeks gestation. J Clin Endocrinol Metab. 2014;99(12):E2668-72.
10. Männistö T, Vääräsmäki M, Pouta A, et al. Thyroid dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complications and maternal morbidity in later life. J Clin Endocrinol Metab. 2010;95(3):1084–94.
11. Biondi B, Kahaly GJ, Robertson RP. Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders. Endocr Rev. 2019;40(3):789–824.
12. Chaker L, Ligthart S, Korevaar TI, et al. Thyroid function and risk of type 2 diabetes: a population-based prospective cohort study. BMC Med. 2016;14(1):150.
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.
14. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. Int J Mol Sci. 2018. 19(11).
15. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081–125.
Weinert LS. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy: comment to the International Association of Diabetes and Pregnancy Study Groups Consensus Panel. Diabetes Care. 2010; 33(7): e97; author reply e98.

17. Ying H, Tang YP, Bao YR, et al. Maternal TSH level and TPOAb status in early pregnancy and their relationship to the risk of gestational diabetes mellitus. Endocrine. 2016;54(3):742–50.

18. Karakosta P, Alegakis D, Georgiou V, et al. Thyroid dysfunction and autoantibodies in early pregnancy are associated with increased risk of gestational diabetes and adverse birth outcomes. J Clin Endocrinol Metab. 2012;97(12):4464–72.

19. Stohl HE, Ouzounian J, Rick AM, Hueppchen NA, Bienstock JL. Thyroid disease and gestational diabetes mellitus (GDM): is there a connection. J Matern Fetal Neonatal Med. 2013;26(11):1139–42.

20. Tudela CM, Casey BM, McIntire DD, Cunningham FG. Relationship of subclinical thyroid disease to the incidence of gestational diabetes. Obstet Gynecol. 2012;119(5):983–8.

21. Diagnostic criteria and classification. of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diabetes Res Clin Pract. 2014;103(3):341–63.

22. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Suppl 1):14–80.

23. Liu H, Shan Z, Li C, et al. Maternal subclinical hypothyroidism, thyroid autoimmunity, and the risk of miscarriage: a prospective cohort study. Thyroid. 2014;24(11):1642–9.

24. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315–89.

Figures

![Flow chart showing the selection of the finally included women in the study.](image-url)